Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: wbASSETt who wrote (253)	7/13/2000 12:51:36 PM
From: Mikeh	Read Replies (1) \| Respond to of 268

On CBS Marketwatch ... King Pharmaceuticals (KG: news, msgs) agreed to merge with Jones Pharma Inc. (JMED: news, msgs) in a stock swap valued at $3.4 billion. Based on a 1.125-to-1 exchange ratio, the deal values each Jones Pharma share at $51.12. King expects the acquisition to add to earnings immediately after its completion, excluding items. King sees earnings growth of 3-to-4 percent on a per share basis in 2001. The companies expect the deal to close by the end of the year. King is halted at 45 7/16, while Jones Pharma is stopped at 43 1/8.